Lilly to expand partnership with diagnostic firm
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Pharmaceutical
Articles
Lilly halts late-stage testing of rheumatoid arthritis drug
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
Struggling Greenwood biotech firm finds buyer
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
Lilly aims to submit five new drugs for approval
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
Law firm adds pharmacy practice
Hall Render Killian Heath & Lyman will draw on existing expertise within the firm to create the 10-member group.
Once-thriving drug lab in turnaround mode
Two years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the double-digit rates of growth that made it a local star.
Greenwood seeks funds back from drugmaker with big plans
Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, was declared in default on $8.4 million in incentives from the city of Greenwood.
Lilly’s Amyvid receives European approval
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
Lilly competitor gets backing on diabetes drug
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Lilly settles with four sisters in DES cancer case
Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
Drug sold by Lilly caused cancer, women claim at Boston trial
In opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen known as DES causes breast cancer in the daughters of women who took it.
Indiana to receive nearly $793K in Amgen settlement
Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.
Lilly OKs $1.5B share buyback, first quarter dividend
Indianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program, which the company expects to complete next year.
Lilly finds solace in new Alzheimer’s study
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
Lilly discontinues late-stage trial in rheumatoid arthritis
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Lilly plans another study for Alzheimer’s drug
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
Lilly chief says China too slow in approving new drugs
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
EU reviews cancer drug from Endocyte, Merck
Merck & Co. and Endocyte Inc. said Tuesday that European Union regulators will review their drug vintafolide as a treatment for ovarian cancer.
Drugmakers collaborate to facilitate drug tests
Eli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests of experimental drugs up and running more quickly and efficiently.
Indy loses promising health startup
LabDoor, which soon will launch an iPhone app that assigns A-F grades to over-the-counter vitamins and medicines, moved last month from Indianapolis to San Francisco, where it received $100,000 in startup financing.